Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Oxford BioMedica PLC

Healthcare GB OXB

600.0GBX
28.00(4.90%)

Last update at 2026-06-04T15:35:00Z

Day Range

571.00606.00
LowHigh

52 Week Range

270.00962.00
LowHigh

Fundamentals

  • Previous Close 572.00
  • Market Cap683.08M
  • Volume367747
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-18.26200M
  • Revenue TTM168.74M
  • Revenue Per Share TTM1.51
  • Gross Profit TTM 65.98M
  • Diluted EPS TTM-0.27

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -31.93600M -47.26500M -188.52700M -45.97600M 19.88M
Minority interest 0.52M 5.42M 26.67M 6.00M -
Net income -30.12800M -43.19000M -157.49000M -45.15900M 19.01M
Selling general administrative 36.76M 29.42M 25.41M 28.22M 15.15M
Selling and marketing expenses - - 0.07M - -
Gross profit 65.98M 53.02M 39.73M 69.18M 82.64M
Reconciled depreciation 19.84M 22.43M 28.71M 26.36M 12.46M
Ebit - -37.42600M -177.32800M -51.55800M 20.77M
Ebitda -33.54300M -14.33300M -148.61800M -24.22600M 33.39M
Depreciation and amortization - 23.09M 28.71M 27.33M 12.62M
Non operating income net other - - - - -
Operating income -33.54300M -39.37500M -184.17400M -51.55800M 20.77M
Other operating expenses 202.28M 168.17M 273.71M 191.55M 121.86M
Interest expense 17.43M 9.84M 11.20M 16.73M 0.89M
Tax provision -1.29100M 1.34M -4.36500M -0.81700M 0.87M
Interest income 5.18M 3.24M 4.91M 0.97M 0.00000M
Net interest income -9.32100M -7.26900M -6.28900M -15.75600M -0.88800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.29100M 1.34M -4.36500M -0.81700M 0.87M
Total revenue 168.74M 128.80M 89.54M 139.99M 142.80M
Total operating expenses 99.52M 92.40M 223.90M 120.74M 61.71M
Cost of revenue 102.76M 75.78M 49.81M 70.81M 60.16M
Total other income expense net 1.61M -7.89000M -4.35300M 5.58M -0.88800M
Discontinued operations - - - - -
Net income from continuing ops -30.64500M -48.60900M -184.16200M -45.15900M 19.01M
Net income applicable to common shares - - - - 19.01M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 325.72M 231.64M 252.34M 460.18M 237.23M
Intangible assets 25.17M 29.22M 30.98M 105.22M 0.05M
Earning assets - - - - -
Other current assets 6.26M 16.86M 11.40M - 45.30M
Total liab 234.37M 171.16M 174.51M 223.99M 49.89M
Total stockholder equity 91.35M 57.05M 74.01M 204.65M 187.34M
Deferred long term liab - - - - -
Other current liab 63.95M 44.29M 29.48M 42.76M 27.19M
Common stock - 52.98M 48.40M 48.13M 43.09M
Capital stock 60.38M 52.98M 48.40M 48.13M 43.09M
Retained earnings -422.35100M -399.50000M -352.91800M -198.54500M -165.80600M
Other liab - - - - 8.10M
Good will 0.00000M 0.00000M 0.00000M 0.66M -
Other assets - - - - 3.60M
Cash 96.88M 60.65M 103.72M 141.28M 108.94M
Cash and equivalents - - - - -
Total current liabilities 84.22M 58.32M 44.31M 59.66M 33.31M
Current deferred revenue - 24.19M 22.11M - -
Net debt 9.76M 48.11M 7.74M -27.00400M -99.60300M
Short term debt 6.06M 4.42M 7.31M 3.29M 0.85M
Short long term debt 0.00000M 0.28M 0.00000M - -
Short long term debt total 106.64M 108.76M 111.46M 114.28M 9.34M
Other stockholder equity 513.70M 394.86M 380.33M 355.07M 310.06M
Property plant equipment - - - - 69.73M
Total current assets 185.65M 133.19M 141.33M 215.50M 163.84M
Long term investments - - - - -
Net tangible assets - - - - 187.29M
Short term investments - - - 0.02M 0.07M
Net receivables 65.18M 42.11M 13.34M 34.11M 22.40M
Long term debt 41.49M 39.79M 38.53M 39.78M -
Inventory 17.33M 13.57M 12.87M 12.62M 9.52M
Accounts payable 14.21M 9.61M 6.05M 13.60M 5.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 8.71M -1.81200M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 4.93M 4.34M 5.01M 3.60M
Deferred long term asset charges - - - - -
Non current assets total 140.07M 98.45M 111.01M 244.68M 73.39M
Capital lease obligations 106.64M 68.69M 72.92M 74.50M 9.34M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 5.63M 2.81M -56.46200M -9.46100M
Change to liabilities - - - - -17.19100M
Total cashflows from investing activities -8.09800M 5.63M 2.81M - -9.46100M
Net borrowings 3.18M -0.46600M 0.00000M - -4.52000M
Total cash from financing activities 50.59M 2.91M -12.70300M 98.62M 46.21M
Change to operating activities - - - - -
Net income -30.12800M -47.26500M -157.49000M -45.97600M 19.88M
Change in cash 36.23M -43.06600M -37.56900M 32.34M 62.20M
Begin period cash flow 60.65M 103.72M 141.28M 108.94M 46.74M
End period cash flow 96.88M 60.65M 103.72M 141.28M 108.94M
Total cash from operating activities -5.45200M -50.62800M -28.51700M -12.61500M 25.45M
Issuance of capital stock 58.06M 17.53M 0.65M 80.15M 51.60M
Depreciation 19.84M 22.43M 28.71M 26.36M 12.46M
Other cashflows from investing activities - 4.12M 12.64M - -
Dividends paid - - - - -
Change to inventory -1.84700M 2.19M -0.24700M 0.67M -2.60900M
Change to account receivables -21.65800M -33.33800M 28.79M - 6.89M
Sale purchase of stock - - - - -
Other cashflows from financing activities -10.64400M -14.15200M -10.23700M 49.89M -5.39300M
Change to netincome - - - - 6.90M
Capital expenditures 4.76M 7.50M 9.83M 16.30M 9.46M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.23M -34.38300M 17.46M 4.91M -12.90900M
Stock based compensation 4.68M 1.69M 3.52M 6.47M 3.98M
Other non cash items 21.45M 8.59M 79.29M -4.38100M 1.05M
Free cash flow -10.21300M -58.12400M -38.34900M -28.91100M 15.99M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OXB
Oxford BioMedica PLC		 28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
GNS
Genus PLC		 38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
AVCT
Avacta Group PLC		 - -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368
IBT
International Biotechnology Trust plc		 28.00 2.99% 966.00 - 714.29 16.40 1.20 15.60

Reports Covered

Stock Research & News

View All

Profile

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Oxford BioMedica PLC

Windrush Court, Oxford, United Kingdom, OX4 6LT

Key Executives

Name Title Year Born
Dr. Roch Doliveux Interim CEO & Chairman NA
Mr. Stuart Paynter CFO, Company Sec. & Director 1974
Mr. Nick Page Chief Operations Officer NA
Dr. James Miskin Ph.D. Chief Technical Officer NA
Dr. Kyriacos Mitrophanous Ph.D. Chief Scientific Officer NA
Mr. Matthew Treagus Chief Information Officer NA
Sophia Bolhassan Head of Investor Relations NA
Ms. Natalie Louise Walter Gen. Counsel NA
Dr. Jason Slingsby MBA Chief Bus. & Corp. Devel. Officer NA
Ms. Sarah Macleod Head of Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.